Participating in open and frank conversations can be a catalyst for both positive change and a better industry. As we share our perspective you will find:
- Relevant and timely industry information
- Medication trends, and their impact
- Case studies, and the results of their related projects
- Special-subject on-demand webinars
Articles and blogs
Sharing information with the industry is an important part of our mission. Our subject matter experts translate today’s news into comprehensive informational pieces to help you better understand the impact of a recent industry update, trend, or issue.
|
May 24, 2020 · Optum Settlement Solutions
The Centers for Medicare and Medicaid Services (CMS) released an updated Workers’ Compensation Medicare Set-Aside (WCMSA) Reference Guide , Version 3.1., dated May 11, 2020 Read more... |
|
May 20, 2020 · Policy Matters team
Listed below are brief updates on several recent policy developments across the country. Read more... |
|
|
May 05, 2020 · Optum Settlement Solutions
The Centers for Medicare and Medicaid Services (CMS) wants their money back and is going after payers to get conditional payments reimbursed. CMS has been sending notices to payers demanding payment, but many of the notices are going unanswered. That creates a two-fold problem. Interest accrues on the balance, and if there’s no response, the U.S. Treasury could seize the assets of the payer (i.e., carrier or self-insured employer). Read more... |
|
|
April 29, 2020 · Policy Matters team
Listed below are brief updates on several recent policy developments across the country. Read more... |
|
April 20, 2020 · Clinical Connection team
Epidiolex oral solution ‒ the only cannabidiol (CBD) prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat epilepsy ‒ is no longer considered a controlled substance under the federal Controlled Substances Act. Read more... |
|
|
April 10, 2020 · Optum Settlement Solutions
The Workers' Compensation Medicare Set-Aside Portal (WCMSAP) is updated monthly based on Average Wholesale Price (AWP) data from RED BOOK®. Updates include a significant drop in the price of pregabalin (generic of Lyrica®), and a substantial decrease in the price of meloxicam (generic of Mobic®). Read more... |
Page 1 of 14
Subscribe today to receive our latest blogs, articles and more.
Additional Resources
Case Studies
Industry Trends Report
Continuing Education
